IP Library Granted Patent US 9,663,820
Granted Patent B2
US 9,663,820 · App. 14/989,499 · Granted May 30, 2017

Recombinase polymerase amplification

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,663,820
App. No.
14/989,499
Granted
May 30, 2017
Kind
B2
Abstract

This disclosure describes related novel methods for Recombinase-Polymerase Amplification (RPA) of a target DNA that exploit the properties of recombinase and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The disclosed methods have the advantage of not requiring thermocycling or thermophilic enzymes, thus offering easy and affordable implementation and portability relative to other amplification methods. Further disclosed are conditions to enable real-time monitoring of RPA reactions, methods to regulate RPA reactions using light and otherwise, methods to determine the nature of amplified species without a need for gel electrophoresis, methods to improve and optimize signal to noise ratios in RPA reactions, methods to optimize oligonucleotide primer function, methods to control carry-over contamination, and methods to employ sequence-specific third ‘specificity’ probes. Further described are novel properties and approaches for use of probes monitored by light in dynamic recombination environments.

Claims (22)

1. A composition comprising;

at least one recombinase agent;

at least one single stranded DNA binding protein;

at least one reverse transcriptase;

at least one DNA polymerase; and

a crowding agent.

2. The composition of claim 1 , wherein the at least one recombinase is selected from the group consisting of UvsX, RecA, and combinations thereof.

3. The composition of claim 1 , wherein the at least one single stranded DNA binding protein is selected from the group consisting of E. coli SSB, T4 gp32 and combinations thereof.

4. The composition of claim 1 , wherein the at least one polymerase comprises a DNA polymerase with strand displacing properties.

5. The composition of claim 1 , wherein the DNA polymerase is selected from the group consisting of E. coli DNA polymerase I Klenow fragment, B. stearothermophilus polymerase (Bst), B. subtilis Phi-29 polymerase, and B. subtilis polymerase I (Bsu).

6. The composition of claim 1 , wherein the crowding agent is present at a concentration between 1 to 12% of a weight or a volume of the composition.

7. The composition of claim 1 , wherein the crowding agent is selected from the group consisting of polyethylene glycol (PEG), dextran and Ficoll.

8. The composition of claim 7 , wherein the PEG is PEG1450, PEG3000, PEG8000 or PEG10000.

9. The composition of claim 7 , wherein the PEG has a molecular weight between 15000 and 20000.

10. The composition of claim 1 , further comprising ATP or an ATP analog, dNTP(s), or T4 bacteriophage UvsY.

11. The composition of claim 10 , wherein the dNTP(s) is/are selected from the group consisting of dATP, dGTP, dCTP and dTTP.

12. The composition of claim 10 , wherein the ATP or ATP analog is selected from the group consisting of ATP, ATP-γ-S, ATB-β-S, ddATP, and a combination thereof.

13. The composition of claim 1 , the composition further comprising a first nucleic acid primer and optionally a second nucleic acid primer.

14. The composition of claim 13 , wherein the first nucleic acid primer, the second nucleic acid primer, or both is labeled with a detectable label selected from the group consisting of enzymes, enzyme substrates, coenzymes, enzyme inhibitors, fluorescent markers, chromophores, luminescent markers, radioisotopes, and a member of a binding pair.

15. The composition of claim 1 , the composition further comprising a nuclease.

16. The composition of claim 15 , wherein the nuclease is endonuclease IV (Nfo) or 8-oxoguanine DNA glycosylase (fpg).

17. The composition of claim 1 , further comprising a buffer.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2020
From: ALERE SAN DIEGO INC.
To: ABBOTT DIAGNOSTICS SCARBOROUGH, INC.
Reel/Frame 054604/0936 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2016
From: PIEPENBURG, OLAF; WILLIAMS, COLIN H.; ARMES, NIALL A.; STEMPLE, DEREK L.
To: ASM SCIENTIFIC, INC.
Reel/Frame 037959/0420 →
MERGER Recorded Mar 11, 2016
From: TWISTDX, INC.
To: BIOSITE INCORPORATED
Reel/Frame 037959/0583 →
CHANGE OF NAME Recorded Mar 11, 2016
From: ASM SCIENTIFIC, INC.
To: TWISTDX, INC.
Reel/Frame 038068/0132 →
CHANGE OF NAME Recorded Mar 11, 2016
From: BIOSITE INCORPORATED
To: ALERE SAN DIEGO INC.
Reel/Frame 038074/0656 →